ArticleUltrasonography (Seoul, Korea)2026
Adaptive radiofrequency ablation using an Octopus multipurpose electrode for small hepatocellular carcinoma adjacent to critical structures: a prospective single-center pilot feasibility study.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aimed to assess the feasibility, safety, and preliminary oncologic outcomes of an adaptive radiofrequency ablation (RFA) strategy using the Octopus multipurpose (Octopus MP) electrode for small hepatocellular carcinoma (HCC) in anatomically challenging locations. Materials and.
methodsThis prospective, single-center cohort study enrolled 76 patients with 83 small HCCs (≤3 cm) in at-risk locations, including tumors adjacent to heat-sensitive organs, central bile ducts, or major vessels and tumors in capsule-adjacent or subphrenic locations. The Octopus MP electrode incorporates integrated temperature monitoring and a central 19-gauge multipurpose needle for fluid instillation and real-time temperature sensing. An anatomy-driven protocol allocated tumors to combined percutaneous ethanol injection plus RFA (PEI-RFA) or temperature-monitored RFA (TM-RFA). The primary endpoint was the thermal injury rate, and secondary endpoints included technical success, technique efficacy, and local tumor progression (LTP).
resultsThe per-protocol analysis included 45 patients with 51 tumors in the PEI-RFA arm and 31 patients with 32 tumors in the TM-RFA arm. Technical success and 1-month technique efficacy were 100% in both arms. No major complications occurred. Thermal injury was observed in three of 45 patients (6.7%) in the PEI-RFA arm and two of 31 patients (6.5%) in the TM-RFA arm; all events were minor and self-limited. Late clinically insignificant biliary strictures occurred in four of 45 patients (8.9%) in the PEI-RFA arm and one of 31 patients (3.2%) in the TM-RFA arm. Patient-based cumulative LTP rates at 12, 24, and 36 months were 4.44%, 7.13%, and 10.95%, respectively, in the PEI-RFA arm and 3.23%, 3.23%, and 7.41%, respectively, in the TM-RFA arm.
conclusionAn anatomy-driven adaptive strategy using the Octopus MP electrode, which integrates established adjunctive ablation techniques within a single device, was feasible for small HCCs near critical structures and was associated with favorable safety and mid-term local control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.